GMP Compliance – Not Investment – Impresses FDA, Chief Counsel Says
This article was originally published in The Tan Sheet
Executive Summary
Manufacturers should not expect FDA to back off from GMP enforcement actions simply because firms have increased their investment in compliance, FDA Chief Counsel Daniel Troy said during a recent University of Georgia GMP conference
You may also be interested in...
FDA Warning Letter Review Suggests Aggressive Action Needed, Troy Says
The FDA Office of Chief Counsel's review of warning and untitled letters suggests the agency should be taking more aggressive enforcement actions, Chief Counsel Daniel Troy suggested Feb. 21
Schering-Plough Afrin, Lotrimin GMP Shortcomings Cited In FDA-483 Report
Batch validations at a Schering-Plough manufacturing site in Puerto Rico uncovered several problems related to Afrin nasal spray and Lotrimin antifungal, FDA-483 inspection reports show.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC